PHARMACOTHERAPY IN PATIENTS WITH CHRONIC MIGRAINE:

DRUG TREATMENT AND THE USE OF BOTULINIC TOXIN OF TYPE A

Abstract

Chronic Migraine is a disabling disease, with characteristic symptoms that cause suffering to the patient, causing damage to their professional and social life. Pharmacotherapeutic treatment consists of using medications during crises for symptom symptoms, associated with prophylactic pharmacotherapy with the aim of reducing the frequency, duration and intensity of the crises. A multiplicity of drugs used in the treatment of migraine associated with self-medication brings risks to the patient's life arising from adverse effects, effects caused and drug interactions. The simultaneous use of drugs can cause intoxications that cause the worst clinical picture of the patient who can use death. It is perceived the importance of a therapeutic approach that reduces the amount of drugs used and is effective in reducing the symptoms of the disease, bringing greater safety to the patient's health. The present study aims to discuss the pharmacotherapy used in the prophylaxis of Chronic Migraine, emphasizing the benefits of using botulinum toxin type A in the treatment. It is a bibliographic research, of qualitative descriptive nature, developed through the collection of data extracted from pharmacology books, scientific articles and master's theses related to the theme. The use of botulinum toxin type A in the treatment of migration presents itself as a positive therapy, with efficacy proven through clinical studies, with a prolonged effect in reducing the pain caused by the disease and, consequently, with the amount of drugs used in treatment. However, there is a need for new comparative studies that elucidate its benefits in view of its high cost in treatment.